Table 2.

Risk of NHL and NHL subtypes associated with HCV among Connecticut women

Number of subjects
HCV− (%)aHCV+ (%)aOR95% CIb
Controls529 (99.1)5 (0.9)1.0
Cases456 (98.3)8 (1.7)1.9(0.5, 7.3)
Immunologic type
    B cell362 (98.1)7 (1.9)2.0(0.6, 8.2)
    T cell34 (100.0)0 (0.0)
    Other60 (98.4)1 (1.6)1.8(0.0, 16.1)
WHO subtypec
    CLL43 (97.7)1 (2.3)2.5(0.1, 22.7)
    DLBCL133 (98.5)2 (1.5)1.6(0.1, 9.8)
    FL103 (96.3)4 (3.7)4.1(0.8, 19.4)
FL tumor grade
    Low45 (97.8)1 (2.2)2.4(0.0, 21.6)
    Intermediate41 (95.3)2 (4.7)5.2(0.5, 32.6)
    High16 (94.1)1 (5.9)6.6(0.1, 63.8)
P for linear trend < 0.01
  • a (%) represents row percentages.

  • b 95% CIs were calculated using the exact method.

  • c CLL = chronic lymphocytic leukemia/lymphoma; DLBCL = diffuse large B-cell lymphoma; FL = follicular lymphoma.